<?xml version='1.0' encoding='utf-8'?>
<document id="27129005"><sentence text="Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults."><entity charOffset="11-21" id="DDI-PubMed.27129005.s1.e0" text="omeprazole" /><entity charOffset="26-35" id="DDI-PubMed.27129005.s1.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.27129005.s1.e0" e2="DDI-PubMed.27129005.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27129005.s1.e0" e2="DDI-PubMed.27129005.s1.e1" /></sentence><sentence text="This Phase I, randomized, open-label study evaluated the gastric pH-altering effects of omeprazole, a proton pump inhibitor, and the CYP3A enzyme/P-glycoprotein (Pgp)-inhibitory effects of ritonavir, an HIV protease inhibitor, on the pharmacokinetics and safety of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitor GSK2336805 in healthy male and female subjects"><entity charOffset="88-98" id="DDI-PubMed.27129005.s2.e0" text="omeprazole" /><entity charOffset="189-198" id="DDI-PubMed.27129005.s2.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.27129005.s2.e0" e2="DDI-PubMed.27129005.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27129005.s2.e0" e2="DDI-PubMed.27129005.s2.e1" /></sentence><sentence text=" Co-administration of GSK2336805 60 mg with omeprazole decreased GSK2336805 plasma AUC(0-∞) by 10% and Cmax by 18%; no marked effect was observed on t½ "><entity charOffset="44-54" id="DDI-PubMed.27129005.s3.e0" text="omeprazole" /></sentence><sentence text=" Co-administration of GSK2336805 30 mg with ritonavir increased GSK2336805 plasma AUC(0-∞) by 52%, Cmax by 43%, and t½ by 40%; CL/F was decreased by 34%"><entity charOffset="44-53" id="DDI-PubMed.27129005.s4.e0" text="ritonavir" /><entity charOffset="130-131" id="DDI-PubMed.27129005.s4.e1" text="F" /><pair ddi="false" e1="DDI-PubMed.27129005.s4.e0" e2="DDI-PubMed.27129005.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27129005.s4.e0" e2="DDI-PubMed.27129005.s4.e1" /></sentence><sentence text=" All adverse events were minor in intensity" /><sentence text=" The gastric acid-suppressive effect of omeprazole had minimal impact on the extent and rate of GSK2336805 absorption in vivo; therefore, GSK2336805 may be co-administered with omeprazole without concern about lower GSK2336805 exposures and compromised antiviral efficacy"><entity charOffset="40-50" id="DDI-PubMed.27129005.s6.e0" text="omeprazole" /><entity charOffset="177-187" id="DDI-PubMed.27129005.s6.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.27129005.s6.e0" e2="DDI-PubMed.27129005.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27129005.s6.e0" e2="DDI-PubMed.27129005.s6.e1" /></sentence><sentence text=" The modest increases in AUC and Cmax following co-administration of GSK2336805 plus ritonavir suggest that GSK2336805 when given concomitantly with a single CYP3A/Pgp inhibiting drug will not likely require dose adjustment"><entity charOffset="85-94" id="DDI-PubMed.27129005.s7.e0" text="ritonavir" /></sentence><sentence text=" Final dose recommendation will be based on GSK2336805 efficacy and safety profiles from Phase III trials in HCV-infected patients"><entity charOffset="1-9" id="DDI-PubMed.27129005.s8.e0" text="F" /></sentence><sentence text="" /></document>